Filing Flows › Penumbra (PEN) › Recalls, complaints & regulation
Penumbra (PEN): recalls and clinical trials
Penumbra (PEN) beyond its filings: 2 recalls in the last 12 months (2 in five years, 0 Class I); 5 active clinical trials.
Latest recalls
- 2026-10-07 · FDA device · Brand Name: Penumbra System (RED 62 Reperfusion Catheter) Product Name: Penumbra System (RED 62 Reperfusion Catheter) Model/Catalog Number: THNDRRED62SKIT So
- 2026-07-29 · FDA device · Penumbra System RED 68 Reperfusion Catheter REF: RED68KIT
Penumbra's latest quarter
Penumbra, Q3 2026: revenue $410M (+16% year over year), operating margin 12.4%, net earnings $42.3M, operating cash flow $41.5M. The chart follows the revenue to costs, profit and cash.
Questions
Has Penumbra had any recalls?
2 recalls on file over five years from the FDA, CPSC and NHTSA; 2 in the last 12 months.
How many clinical trials does Penumbra have?
5 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.